Anthem Biosciences IPO 2025: Price & Details

Anthem Biosciences IPO is a much-awaited issue of 2025, which is coming to the market as an offer for sale of ₹3,395 crore. The company is a leading CRDMO (Contract Research, Development & Manufacturing Organization) providing end-to-end services to global pharma and biotech companies. Considering the growth and innovation in the healthcare sector, this IPO can be an attractive opportunity for investors.

About Anthem Biosciences Ltd.

Anthem Biosciences Ltd. was started in 2006 with one objective to provide the pharmaceutical industry with one-stop solutions from research to manufacturing. Today, the company has become India’s fastest growing Contract Research, Development and Manufacturing Organization (CRDMO), working with pharma and biotech companies around the world.

Products and Services : The company’s main focus is on the manufacture of fermentation-based APIs (Active Pharmaceutical Ingredients). Its products include probiotics, enzymes, peptides, nutritional actives, vitamin analogs and biosimilars. These products meet global pharma and biotech needs.

Customer network spread across the world : Anthem’s scope is not limited to India only. Today, the company is providing its services in more than 44 countries including America, Europe, Japan. Along with this, the company has more than 550 active customers, ranging from small biotech startups to big pharma companies.

Strength of Research and Projects : As of September 2024, Anthem had a total of 196 projects. These include 170 discovery, 132 early stage, 16 late stage and 13 commercial manufacturing projects. These figures show that the company is not only innovating but also taking them to the market.

Patents and Innovation : Patents are the true identity of any innovation-focused company. Anthem currently has 1 Indian and 7 foreign patents, and has applied for 24 other patents. Many of these patents are related to cutting-edge drug manufacturing processes, such as GLP-1 analogs and glycolipid synthesis.

Strong team, deep expertise : The strength of any research-driven company is its team, and Anthem is far ahead in this regard. More than 600 scientists and experts work here – such as chemists, biologists, microbiologists and engineers. This team takes every project of the company from idea to reality.

Financial Performance

Objective of the Anthem Biosciences Ltd. IPO

Completely Offer for Sale (OFS) : This public issue of Anthem Biosciences Ltd. is completely an Offer for Sale, that is, the company itself is not issuing any new shares. Instead, existing shareholders such as promoters, investors or venture capital firms are selling their stakes in the market. The company will not receive any capital directly in this process.

The company will not get any new funds from the IPO : The entire amount raised from this issue will go to the shareholders who are selling their shares. This means that Anthem Biosciences Ltd. will not get any funding support from this offer. No new capital will be added to the company’s balance sheet and neither will it be used in any new project, debt repayment or capex. The company can only benefit from the exposure and brand value it gets from listing, which can ease the possibilities of raising other capital in the future.

What OFS means for investors : It is very important for investors to know how the company will use the money raised from an IPO. If the company was raising funds to enhance a project, expand or improve its financial position, then the benefit would be directly linked to business growth. But in the case of Anthem Biosciences Ltd., the situation is different. Since it is a pure OFS, it means that the company does not need immediate capital. It also indicates that existing investors may want to partially exit their holdings or the company has now reached a stage where it finds the brand value and transparency that comes from listing more important.

Possible objective of OFS : The main objective behind this offer appears to be that the company wants to provide an exit opportunity to some of its existing investors. Also, after getting listed on the stock exchange, the company will get increased brand credibility and transparency, which can create a positive environment for any future fundraising.

Anthem Biosciences Ltd. IPO Reservation Details

Competitive Strengths of Anthem Biosciences Ltd

Integrated CRDMO platform and global reach : Anthem Biosciences Ltd. is a fully integrated Contract Research, Development & Manufacturing Organization (CRDMO) that provides pharma and biotech companies with the full range of solutions from drug discovery to commercial manufacturing. This end-to-end solution sets the company apart from its competitors and makes it a more reliable choice for clients globally.

Expertise across every stage of drug development : The company’s biggest strength is that it offers services across every stage of the drug life cycle discovery, early stage research, process development, clinical trial manufacturing, and commercial-scale production. This allows companies from small biotech startups to large multinational pharma companies to rely on Anthem for the entire drug development process.

Client network spanning 44+ countries : Anthem’s client base is not only diverse but also global. The company is serving more than 44 countries including the US, Europe, Japan. As of September 2024, the company had more than 550 active customers, many of whom have been associated for a long time. This shows that the company has not only earned trust but also built relationships.

Rapidly growing financial growth : Anthem Biosciences has recorded consistent revenue and profit growth over the last three years. The company’s revenue in FY 2025 was ₹1,930 crore, which is about 30% higher than FY24. PAT (Profit After Tax) also saw a growth of 23% in the same period. The company’s return ratios like ROE and ROCE prove that its financial management is also very strong.

Experienced team of 600+ professionals : The company has a strong team of scientists, chemists, microbiologists and engineers, who are constantly engaged in research and innovation. Anthem’s team of over 600 experts is one of its biggest internal strengths, approaching every project with a scientific approach and guaranteed quality.

Deep Intellectual Property : Anthem has so far secured 7 international and 1 Indian patent, and 24 patent applications are pending in various countries. Many of these patents are related to cutting-edge technologies such as GLP-1 analogs and glycolipid synthesis. This shows that the company is not only service-based but also focuses on knowledge-based value creation.

Strong Relationships with Major Clients : Anthem Biosciences’ history shows that the company has built long-lasting relationships with many of the world’s leading pharma companies. This not only reflects its credibility but also proves how effective Anthem is as a long-term partner.

Potential risks associated with investing in Anthem Biosciences

Business model sensitive to market volatility : Anthem Biosciences is a scientific research-based company whose operations are heavily dependent on global markets and biotech/pharma industry demand. Such a business model is sensitive to stock market volatility and global economic trends. If research investment in a particular area declines or there is a regulatory ban on new drugs, the company’s revenue may be affected.

Long project cycle and possibility of revenue delays : The nature of the CRDMO industry is such that the cycle from research and development to product commercialization is very long. Due to this, the company does not get immediate returns from any project. If there is a technical delay in a major project or budget cuts are made by the client, the company may face a decline or temporary stagnation in revenue.

High dependence on the same type of clients : Although the company’s client base is spread internationally, a large portion of clients come from the pharma and biotech industry. If there is a global recession or investment slowdown in this particular sector, the company may face challenges such as a drop in client retention and order pipeline.

Pressure of technological innovation : In sectors such as pharmaceutical and biotechnology, new technologies and scientific approaches emerge every year. Anthem has to constantly upgrade its research infrastructure and manufacturing capabilities. If the company is unable to keep itself updated with these changes, it may not only lag behind the competition but also client loyalty may be affected.

Licensing and compliance complexities : Companies involved in drug manufacturing and research have to adhere to strict norms of multiple regulatory bodies in different countries. Be it the European Union’s GMP guidelines or the US FDA requirements any lapse or delay in compliance can directly impact the company’s reputation and operations.

Anthem Biosciences Ltd GMP

As of July 11, the grey market premium of the Smartworks IPO has reached ₹32, which represents a premium of about 7.9% over the upper band of the issue at ₹407. This is a clear indication that the market is expecting initial gains in the shares after listing.

Also Read : Top Women Investors in India 2025

Final Thoughts

Anthem Biosciences Ltd. is a research and innovation based pharma company, whose IPO is completely Offer for Sale. That is, the company will not get any new money from this issue. Nevertheless, its strong financial growth, international clients and technological expertise make it interesting for long term investment. But before investing, its valuation and current market conditions must be carefully understood.